Total Payments
$14,702
2024 Payments
$212.08
Companies
77
Transactions
577
Medicare Patients
404
Medicare Billing
$72,551
Payment Breakdown by Category
Food & Beverage$11,999 (81.6%)
Gifts$1,797 (12.2%)
Education$606.80 (4.1%)
Other$299.10 (2.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,999 | 549 | 81.6% |
| Gift | $1,797 | 17 | 12.2% |
| Education | $606.80 | 8 | 4.1% |
| Long term medical supply or device loan | $299.10 | 3 | 2.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,803 | 61 | $0 (2024) |
| Incyte Corporation | $1,094 | 38 | $0 (2024) |
| Janssen Biotech, Inc. | $932.02 | 50 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $724.94 | 32 | $0 (2023) |
| Amgen Inc. | $514.92 | 18 | $0 (2023) |
| EMD Serono, Inc. | $446.93 | 26 | $0 (2023) |
| Merck Sharp & Dohme LLC | $400.81 | 23 | $0 (2024) |
| BeiGene USA, Inc. | $382.23 | 16 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $381.93 | 18 | $0 (2023) |
| Celgene Corporation | $323.02 | 15 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $212.08 | 5 | Pharmacosmos Therapeutics Inc. ($118.49) |
| 2023 | $1,405 | 55 | GlaxoSmithKline, LLC. ($195.47) |
| 2022 | $1,022 | 45 | Incyte Corporation ($119.61) |
| 2021 | $3,466 | 161 | Novartis Pharmaceuticals Corporation ($454.93) |
| 2020 | $2,775 | 118 | Novartis Pharmaceuticals Corporation ($831.30) |
| 2019 | $5,153 | 161 | Novartis Pharmaceuticals Corporation ($1,414) |
| 2018 | $555.98 | 27 | Medtronic Vascular, Inc. ($147.34) |
| 2017 | $112.43 | 5 | E.R. Squibb & Sons, L.L.C. ($79.76) |
All Payment Transactions
577 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/25/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $118.49 | General |
| Category: HEMATOLOGY | ||||||
| 02/02/2024 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $25.89 | General |
| Category: Oncology | ||||||
| 01/31/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.69 | General |
| 01/23/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $25.20 | General |
| Category: ONCOLOGY | ||||||
| 01/23/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $19.81 | General |
| Category: Immunology | ||||||
| 11/18/2023 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $19.35 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2023 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: ONCOLOGY | ||||||
| 10/27/2023 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: ONCOLOGY | ||||||
| 09/23/2023 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $14.33 | General |
| Category: ONCOLOGY | ||||||
| 08/05/2023 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $13.85 | General |
| Category: ONCOLOGY | ||||||
| 07/15/2023 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $14.77 | General |
| Category: ONCOLOGY | ||||||
| 06/05/2023 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $12.29 | General |
| Category: ONCOLOGY | ||||||
| 05/31/2023 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $28.39 | General |
| Category: Oncology | ||||||
| 05/31/2023 | PFIZER INC. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $17.52 | General |
| Category: HEMATOLOGY | ||||||
| 05/24/2023 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $14.08 | General |
| Category: Oncology | ||||||
| 05/23/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $26.27 | General |
| Category: ONCOLOGY | ||||||
| 05/15/2023 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $18.40 | General |
| Category: ONCOLOGY | ||||||
| 05/12/2023 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $20.14 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 05/02/2023 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $9.87 | General |
| Category: ONCOLOGY | ||||||
| 05/01/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $24.46 | General |
| Category: ONCOLOGY | ||||||
| 05/01/2023 | Amgen Inc. | Vectibix (Biological) | Food and Beverage | In-kind items and services | $16.61 | General |
| Category: Oncology | ||||||
| 04/25/2023 | EMD Serono, Inc. | BAVENCIO (Drug) | Food and Beverage | Cash or cash equivalent | $24.41 | General |
| Category: Oncology | ||||||
| 04/20/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $23.08 | General |
| Category: ONCOLOGY | ||||||
| 04/20/2023 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $16.11 | General |
| Category: ONCOLOGY | ||||||
| 04/19/2023 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $19.57 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 2 | 31 | 33 | $10,789 | $3,068 |
| 2021 | 11 | 257 | 632 | $118,794 | $48,837 |
| 2020 | 6 | 116 | 253 | $57,922 | $20,647 |
Total Patients
404
Total Services
918
Medicare Billing
$72,551
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 12 | 13 | $5,164 | $1,741 | 33.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 19 | 20 | $5,625 | $1,327 | 23.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 70 | 172 | $45,230 | $17,829 | 39.4% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 12 | 67 | $21,440 | $10,720 | 50.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 65 | 128 | $23,651 | $9,302 | 39.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 12 | 56 | $8,123 | $3,271 | 40.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 15 | 18 | $6,700 | $2,533 | 37.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 17 | 22 | $5,861 | $2,156 | 36.8% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 16 | 20 | $3,707 | $1,415 | 38.2% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 13 | 13 | $2,984 | $1,146 | 38.4% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 11 | 24 | $682.30 | $278.26 | 40.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 14 | 34 | $204.00 | $102.00 | 50.0% |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 2021 | 12 | 78 | $212.55 | $84.94 | 40.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 36 | 84 | $21,363 | $6,693 | 31.3% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2020 | 11 | 32 | $9,280 | $4,824 | 52.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 22 | 39 | $13,721 | $4,482 | 32.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 17 | 17 | $8,302 | $2,786 | 33.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 18 | 21 | $5,082 | $1,803 | 35.5% |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 2020 | 12 | 60 | $174.00 | $58.29 | 33.5% |
About Dr. Sanda Morar, MD
Dr. Sanda Morar, MD is a Medical Oncology healthcare provider based in Las Vegas, Nevada. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1326155391.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sanda Morar, MD has received a total of $14,702 in payments from pharmaceutical and medical device companies, with $212.08 received in 2024. These payments were reported across 577 transactions from 77 companies. The most common payment nature is "Food and Beverage" ($11,999).
As a Medicare-enrolled provider, Morar has provided services to 404 Medicare beneficiaries, totaling 918 services with total Medicare billing of $72,551. Data is available for 3 years (2020–2022), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Las Vegas, NV
- Active Since 08/24/2006
- Last Updated 10/03/2018
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1326155391
Products in Payments
- KISQALI (Drug) $1,943
- IMBRUVICA (Drug) $585.24
- JAKAFI (Drug) $553.14
- LIBTAYO (Biological) $393.32
- BRUKINSA (Drug) $382.23
- KEYTRUDA (Biological) $353.98
- TAGRISSO (Drug) $270.51
- GILOTRIF (Drug) $255.97
- ZEJULA (Drug) $255.73
- Kyprolis (Biological) $253.15
- PROMACTA (Drug) $238.37
- ERLEADA (Drug) $230.88
- Lenvima (Drug) $203.50
- LifeVest (Device) $200.00
- OPDIVO (Biological) $184.74
- Bavencio (Drug) $170.87
- TEGSEDI (Drug) $166.82
- CALQUENCE (Drug) $160.59
- MONJUVI (Drug) $160.45
- Tavalisse (Drug) $158.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Las Vegas
Dr. Brian Vicuna, Md, MD
Medical Oncology — Payments: $97,453
Medical Oncology $97,453
Dr. Raja Mehdi, Md, MD
Medical Oncology — Payments: $7,111
Medical Oncology $7,111
Dr. Okechukwu Obi, Md, MD
Medical Oncology — Payments: $686.55
Medical Oncology $686.55
Dr. Stephen Iacoboni, Md, MD
Medical Oncology — Payments: $680.18
Medical Oncology $680.18
Dr. David Kotlyar, M.d, M.D
Medical Oncology — Payments: $461.54
Medical Oncology $461.54
Mohammad Nagy, M.d, M.D
Medical Oncology — Payments: $248.72
Medical Oncology $248.72